We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG

• https://x.com/Dr_Brian_MD/status/1858268878658514984/photo/1

Super helpful results from COVER study, holding JAK or IL17 for COVID boosters Antibody titers went up regardless of holding Holding caused flares (14-25% increase!) Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest https://t.co/Mf89dWrRWz

• https://x.com/EBRheum/status/1858267620316688737/photo/1

Comparison of infection risk across b/tsDMARDs in IA in real-world study Treatment with ➡️Rituximab ➡️JAKi ➡️Anti-IL6 assoc with ⬆️⬆️ risk of severe infection compared to TNFi A reminder to consider comorbidities & infection risk in selecting b/tsDMARDs Ab1716 #ACR24 @RheumNow

Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH Encouraging data for JAKs in this disease; need proper trials #ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip

• Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease …
• https://x.com/EBRheum/status/1858261077311529458/photo/1
• https://x.com/EBRheum/status/1858261077311529458/photo/1
• https://x.com/EBRheum/status/1858261077311529458/photo/1

Wu et al. MDA5-DM. Propensity-score cohort study. 672 patients. Tofacitinib vs CNI. Primary outcome 1 year death or lung transplant. HR 0.70 favouring tofacitinib. @RheumNow #ACR24 Abstr#1736 https://t.co/A0aHhp1q9c https://t.co/LbutJDBllr

• Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstiti…
• https://x.com/RichardPAConway/status/1858261329993212326/photo/1

Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec

• Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Rando…
• https://x.com/RichardPAConway/status/1858251010788991334/photo/1